Meeder Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.83K Buy
153
+81
+113% +$4.6K ﹤0.01% 773
2026
Q2
$5.71K Sell
72
-80
-53% -$6.02K ﹤0.01% 817
2026
Q1
$11.4K Sell
152
-564
-79% -$44.5K ﹤0.01% 665
2025
Q4
$56.6K Buy
716
+3
+0.4% +$226 ﹤0.01% 380
2025
Q3
$46.6K Buy
713
+614
+620% +$30K ﹤0.01% 320
2025
Q2
$3.91K Buy
99
+4
+4% +$131 ﹤0.01% 746
2025
Q1
$2.87K Buy
+95
New +$3.11K ﹤0.01% 838
2022
Q4
– Sell
-186
Closed -$8K – 1371
2022
Q3
$8K Hold
186
– – ﹤0.01% 1403
2022
Q2
$7K Hold
186
– – ﹤0.01% 1511
2022
Q1
$7K Buy
+186
New +$6.09K ﹤0.01% 1676
2021
Q4
– Sell
-14
Closed – – 1731
2021
Q3
$0 Hold
14
– – ﹤0.01% 2554
2021
Q2
$1K Hold
14
– – ﹤0.01% 2346
2021
Q1
$1K Buy
14
+1
+8% +$56 ﹤0.01% 2217
2020
Q4
$1K Sell
13
-18
-58% -$897 ﹤0.01% 1669
2020
Q3
$1K Sell
31
-30
-49% -$1.67K ﹤0.01% 1990
2020
Q2
$4K Buy
61
+19
+45% +$1.06K ﹤0.01% 1587
2020
Q1
$2K Sell
42
-3,574
-99% -$199K ﹤0.01% 2092
2019
Q4
$219K Buy
3,616
+3,562
+6,596% +$212K 0.01% 577
2019
Q3
$3K Buy
54
+27
+100% +$1.76K ﹤0.01% 1878
2019
Q2
$2K Sell
27
-2,229
-99% -$158K ﹤0.01% 1863
2019
Q1
$184K Buy
+2,256
New +$146K 0.01% 563
2018
Q3
– Sell
-112
Closed -$4.67K – 1611
2018
Q2
$4.67K Buy
+112
New +$4.96K ﹤0.01% 1290
2018
Q1
– Sell
-309
Closed -$16K – 1640
2017
Q4
$16K Buy
309
+265
+602% +$14.5K ﹤0.01% 995
2017
Q3
$2K Buy
+44
New +$2.3K ﹤0.01% 1456
2017
Q2
– Sell
-410
Closed -$16K – 1760
2017
Q1
$16K Sell
410
-1,333
-76% -$59.9K ﹤0.01% 759
2016
Q4
$83K Buy
+1,743
New +$69K 0.01% 540

Other funds holding IONS

Meeder Asset Management's IONS Position: Q3 2026 in Review

Meeder Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 113% in Q3 2026, buying an estimated $4.6K and bringing the position to 153 shares worth $6.83K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Meeder Asset Management first reported a position in IONS in Q4 2016 and has held it in 26 quarters since. The position peaked at $219K in Q4 2019. 465 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Meeder Asset Management held 153 shares of Ionis Pharmaceuticals worth $6.83K as of Q3 2026.
  • Meeder Asset Management bought 81 Ionis Pharmaceuticals shares in Q3 2026, an estimated $4.6K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q3 2026, its #773 holding.
  • Meeder Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 26 quarters since.
  • Meeder Asset Management's Ionis Pharmaceuticals position peaked at $219K in Q4 2019.
  • 465 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Meeder Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.